Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / SUPN - Supernus Pharmaceuticals drops 2.7% on 2022 guidance

SUPN - Supernus Pharmaceuticals drops 2.7% on 2022 guidance

Supernus Pharmaceuticals Inc.
Biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases Supernus Pharmaceuticals (NASDAQ:SUPN) reiterates FY2022 financial guidance initially announced on February 28, 2022. Expects total revenues between $640M - $680M (vs. consensus $676.76M); Combined R&D and SG&A expenses $460M - $490M; Operating earnings $20M - $40M; Effective tax rate 25% - 28%. Operating earnings - GAAP $20M - $40M; Operating earnings - non-GAAP $130M - $165M. Stock drops 2.7% during after-market hours. More analysis on the stock by contributor who writes: 'Supernus: New Beginnings'

For further details see:

Supernus Pharmaceuticals drops 2.7% on 2022 guidance
Stock Information
Company Name: Supernus Pharmaceuticals Inc.
Stock Symbol: SUPN
Market: NASDAQ
Website: supernus.com
Menu
SUPN SUPN Quote SUPN Short SUPN News SUPN Articles SUPN Message Board
Get SUPN Alerts

News, Short Squeeze, Breakout and More Instantly...